Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

Key facts

Study ID

NCT00555724

Run by

Biogen

People needed

40

Starts

2008-01-01

Expected to finish

2010-07-01

Last updated by the study team

2017-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older at the time of informed consent
• Relapsed or refractory solid tumors following standard therapy.
• ECOG Performance Status 0 or 1.

You may not qualify if…

• History of insulin-dependent diabetes, type 2 diabetes, or hemoglobin A1c >6% at screening.
• History of myocardial infarction within 12 months prior to Day 1 or chronic heart failure.
• Known central nervous system or brain metastases.
• Prior anti-IGF-1R therapy of any kind.
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — Aurora, Colorado, United States
• Research Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.